Upstream Bio, Inc.
Close on Oct 19, 2026
- Market cap
- $152.79M
- P/E (TTM)
- –
- Dividend yield
- –
About Upstream Bio
Pharmaceutical Preparations, SIC 2834
The company is a clinical-stage biotechnology company that focuses on developing treatments for severe inflammatory and respiratory disorders. Its primary investigational drug candidate is verekitug, a recombinant human monoclonal antibody designed to bind and inhibit the Thymic Stromal Lymphopoietin receptor. The company is advancing this product candidate across clinical programs for indications such as severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Its target patient population consists of individuals suffering from severe immune-mediated conditions underserved by current standards of care.
The company evaluates verekitug through multi-national clinical trials, having administered the drug candidate to approximately 500 trial participants across five clinical studies. In addition, its research activities include conducting Japanese ethnobridging evaluations as part of its global clinical development efforts. The provided text does not disclose the location of the company's headquarters or any operational facilities.
Summary of the business section of Upstream Bio's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Upstream Bio, Inc.
- Headquarters
- Waltham, MA
- Address
- 890 Winter Street, Suite 200 02451
- Phone
- (781) 208-2466
- Employees
- 75, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- UPB
- Exchange
- Nasdaq
- IPO date
- Oct 11, 2024
- Shares outstanding
- 55M, Aug 4, 2026
- Public float
- $467.86M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 2022626
- CUSIP
- 91678A107
- ISIN
- US91678A1079
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Everett Rand Sutherland | Chief Executive Officer, Director | 68,717 |
| Aaron Deykin | Chief Medical Officer | 32,302 |
| Allison Ambrose | General Counsel | 15,563 |
| Michael Gray | CFO and COO | 27,942 |
| Adam Houghton | Chief Business Officer | 22,901 |
| Erez Chimovits | Director | 4,554,873 |
| Harold Edward Fleming | Director | – |
| Liam Ratcliffe | Director | – |
| Marcella K. Ruddy | Director | – |
| Ronald C. Renaud JR | Director | – |
| Daniella Beckman | Director | – |
Employees
Headcount reported in annual reports
“As of March 20, 2026, we had 75 full-time employees, 22 of which have M.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 11, 2024 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 8, 2024 | Listing | Registration of securities on an exchange (Form 8-A) |